Full Year 2024 Innate Pharma SA Earnings Call Transcript
Key Points
- Innate Pharma SA (IPHA) successfully recruited the first patients into the phase 1 dose-finding trial for IPH 65, marking a critical step in its clinical development.
- IPH 45, a nectin-4 targeted ADC, dosed its first patients in January 2025 following IND clearance, indicating progress in their ADC program.
- Lecutumab received FDA breakthrough therapy designation, potentially accelerating its approval process.
- The company has a robust pipeline with 8 innovative assets currently in the clinic, showcasing their R&D productivity.
- Innate Pharma SA (IPHA) has sufficient cash to fund operations through mid-2026, providing financial stability for ongoing projects.
- Operating expenses from continuing operations amounted to 71.7 million in 2024, with a significant portion allocated to R&D, indicating high operational costs.
- General and administrative expenses increased by 1.4 million compared to the previous year, reflecting rising operational costs.
- IPH 6,401's development is being refocused from multiple myeloma to autoimmune diseases, which may be seen as a speculative move.
- The company is still in discussions for partnerships, indicating potential delays in commercialization and strategic collaborations.
- The competitive landscape in the non-Hodgkin lymphoma space is crowded, posing challenges for IPH 6,501's market entry.
Hello and welcome to the innate Pharma full year 2024 financial results and business update. All lines have been placed on mute to prevent any background noise.
After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press one on your telephone keypad. I would now like to turn the conference over to Henry Wheeler, Vice President, investor relations and communications. You may begin.
Thank you. Good morning, good afternoon, and welcome, everyone. This morning, innate issued a press release for our full year 2024 business update and financial results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On slide 2, before we start, I would like to remind you that we will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |


